News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma
Heidelberg Pharma advances to Cohort 9 in Phase I/IIa trial of lead ATAC candidate HDP-101 in multiple myeloma, demonstrating favorable safety profile and early signs of clinical activity -
-
-
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
Heidelberg Pharma reduces costs and focuses on lead ADC candidate HDP-101 due to delayed milestone payment. Extensive cost-saving measures implemented -
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
Heidelberg Pharma significantly reduces operating costs and focuses on lead ADC candidate HDP-101 due to delayed milestone payment. Extensive cost-saving measures implemented
